|
 |
|
|
|||
|
 |
|
Nov. 24, 2014 Source: Zoetis news release Zoetis Inc. (NYSE:ZTS) today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite. This acquisition will strengthen Zoetis' companion animal product portfolio and expand its diagnostics business as more pets are being treated for pain and serious illnesses, such as cancer and diabetes. Headquartered in Abbott Park, Illinois, Abbott Animal Health has a presence in nearly 20 countries and holds a market-leading position with products in anesthesia, fluid therapy, pain, oncology and diabetes monitoring. "The addition of Abbott Animal Health assets is an excellent complement to the Zoetis companion animal business and addresses the challenges our customers face today in effectively raising and caring for animals that are living longer and receiving more intensive medical and surgical treatment," said Zoetis Chief Executive Officer Juan Ramón Alaix. "The transaction is aligned with our value creation strategy to deploy capital to acquire products that enhance our portfolio. This acquisition strengthens our pain portfolio and our diagnostics business so we can deliver more customized solutions to veterinarians." Going forward, Zoetis remains committed to its strategy of acquiring complementary businesses and products that can generate sustained value to shareholders. Zoetis has the skill and experience to integrate new businesses, having led successful integrations such as Alpharma Animal Health over the last several years. Through all of its acquisitions, Zoetis has maintained its commitment to customers and uninterrupted service. No other terms of the transaction are being disclosed. The transaction is expected to close in the first quarter of 2015, pending the successful completion of customary regulatory and legal reviews. Addressing Demand for Specialty Veterinary Care Zoetis' acquisition comes at a time when spending on companion animal healthcare is increasing, and this acquisition broadens the range of Zoetis pharmaceutical and diagnostics solutions to help pets live longer and healthier lives. "Zoetis is well suited to build on the leadership position of Abbott Animal Health in the veterinary surgical suite," said Zoetis Group President Kristin Peck, who oversees the company's Strategy and Corporate Development organization. "We believe Zoetis' scale, industry-leading field force, and global presence will rapidly expand both the reach and penetration of these leading brands." With this acquisition, Zoetis adds trusted brands to its portfolio such as PropoFlo™ a versatile product for general anesthesia; Simbadol™ a feline pain reliever that reduces the need for overnight dosing after feline surgery; and AlphaTRAK® a glucose monitoring system used by Veterinarians for diabetes diagnosis or monitoring. These are just a few of the products that will enable Zoetis to serve the veterinary surgical suite with an even wider range of solutions. The acquisition also brings novel cancer and pain compounds to the Zoetis pipeline for further development. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
